Piers J. Ingram

876 total citations
21 papers, 438 citations indexed

About

Piers J. Ingram is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Piers J. Ingram has authored 21 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Immunology. Recurrent topics in Piers J. Ingram's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Gene Regulatory Network Analysis (4 papers). Piers J. Ingram is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Gene Regulatory Network Analysis (4 papers). Piers J. Ingram collaborates with scholars based in United Kingdom, United States and Singapore. Piers J. Ingram's co-authors include Michael P. H. Stumpf, Jaroslav Stark, Jerome D. Boyd‐Kirkup, Dipti Thakkar, Ken Haynes, Ruian Ke, Thomas Thorne, Konrad Paszkiewicz, Jonathan Swire and Siyu Guan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Piers J. Ingram

21 papers receiving 426 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Piers J. Ingram United Kingdom	8	289	88	76	56	36	21	438
Dan Tenenbaum United States	5	592 2.0×	35 0.4×	53 0.7×	66 1.2×	44 1.2×	8	788
Max Schelker Germany	7	318 1.1×	81 0.9×	73 1.0×	24 0.4×	12 0.3×	7	450
Ruth Dannenfelser United States	13	387 1.3×	186 2.1×	122 1.6×	43 0.8×	28 0.8×	19	633
Najl V. Valeyev United Kingdom	10	252 0.9×	32 0.4×	87 1.1×	39 0.7×	18 0.5×	19	444
Ingo Schupp Germany	9	426 1.5×	61 0.7×	75 1.0×	101 1.8×	35 1.0×	10	582
Alberto Calderone Italy	12	521 1.8×	43 0.5×	41 0.5×	41 0.7×	17 0.5×	16	635
Matija Dreze United States	8	671 2.3×	42 0.5×	27 0.4×	59 1.1×	35 1.0×	11	772
Ming-Chih J. Kao United States	5	462 1.6×	82 0.9×	199 2.6×	56 1.0×	16 0.4×	5	702
Paul Brazhnik United States	9	531 1.8×	109 1.2×	12 0.2×	96 1.7×	19 0.5×	12	600
Dan J. Woodcock United Kingdom	10	375 1.3×	46 0.5×	78 1.0×	81 1.4×	19 0.5×	18	620

Countries citing papers authored by Piers J. Ingram

Since Specialization

Citations

This map shows the geographic impact of Piers J. Ingram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Piers J. Ingram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Piers J. Ingram more than expected).

Fields of papers citing papers by Piers J. Ingram

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Piers J. Ingram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Piers J. Ingram. The network helps show where Piers J. Ingram may publish in the future.

Co-authorship network of co-authors of Piers J. Ingram

This figure shows the co-authorship network connecting the top 25 collaborators of Piers J. Ingram. A scholar is included among the top collaborators of Piers J. Ingram based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Piers J. Ingram. Piers J. Ingram is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rasheed, Suhail Ahmed Kabeer, Dipti Thakkar, Akshaya Bansal, et al.. (2023). Abstract 2660: HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models. Cancer Research. 83(7_Supplement). 2660–2660. 2 indexed citations

Bono, Johann S. de, Simon Lord, Christina Yap, et al.. (2023). 687P A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours. Annals of Oncology. 34. S479–S480. 1 indexed citations

Thakkar, Dipti, Warren Lee, Brendon J. Hanson, et al.. (2023). Selective targeting of pathogenic auto-reactive VH4–34 B cells with a rationally developed anti-VH4–34 antibody offers a new therapeutic approach for autoimmune disorders. The Journal of Immunology. 210(Supplement_1). 238.20–238.20. 2 indexed citations

Rodón, Jordi, Joshua J. Gruber, Melinda L. Telli, et al.. (2023). A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). TPS2664–TPS2664. 6 indexed citations

Thakkar, Dipti, Bhushan Dharmadhikari, Siyu Guan, et al.. (2022). Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner. Journal for ImmunoTherapy of Cancer. 10(2). e003382–e003382. 46 indexed citations

Haber, Tom, Bhushan Dharmadhikari, Thomas Müller, et al.. (2022). 623 Trial in progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies. Regular and Young Investigator Award Abstracts. A655–A655. 2 indexed citations

Thakkar, Dipti, Shreya Kar, Namita Gandhi, et al.. (2021). Abstract P197: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1-fusion driven cancers. Molecular Cancer Therapeutics. 20(12_Supplement). P197–P197. 5 indexed citations

DiMascio, Leah, Dipti Thakkar, Namita Gandhi, et al.. (2021). HMBD-002 is a novel, neutralizing, anti-VISTA antibody exhibiting strong preclinical efficacy and safety, being developed as a monotherapy and in combination with pembrolizumab.. Journal of Clinical Oncology. 39(15_suppl). e14569–e14569. 7 indexed citations

DiMascio, Leah, Dipti Thakkar, Siyu Guan, et al.. (2021). 469 A phase 1 first in human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies. Regular and Young Investigator Award Abstracts. A498–A498. 3 indexed citations

10.

Thakkar, Dipti, Vicente Sancenón, Siyu Guan, et al.. (2020). 10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models. Molecular Cancer Therapeutics. 19(2). 490–501. 13 indexed citations

11.

Boyd‐Kirkup, Jerome D., Dipti Thakkar, Konrad Paszkiewicz, & Piers J. Ingram. (2018). Abstract 1729: Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD002, a novel anti-VISTA neutralizing antibody. Cancer Research. 78(13_Supplement). 1729–1729. 6 indexed citations

12.

Boyd‐Kirkup, Jerome D., Dipti Thakkar, Peter Bräuer, et al.. (2017). HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML. Blood. 130. 1378–1378. 18 indexed citations

13.

Ingram, Piers J., Dipti Thakkar, & Jerome D. Boyd‐Kirkup. (2017). Abstract 587: HMBD002, a novel neutralizing antibody targeting a specific epitope on the co-inhibitory immune checkpoint receptor VISTA, displays potent anti-tumor effects in pre-clinical models. Cancer Research. 77(13_Supplement). 587–587. 7 indexed citations

14.

Ke, Ruian, Piers J. Ingram, & Ken Haynes. (2013). An Integrative Model of Ion Regulation in Yeast. PLoS Computational Biology. 9(1). e1002879–e1002879. 37 indexed citations

15.

You, Tao, Piers J. Ingram, Mette D. Jacobsen, et al.. (2012). A systems biology analysis of long and short-term memories of osmotic stress adaptation in fungi. BMC Research Notes. 5(1). 258–258. 32 indexed citations

16.

Fleming, Jason C., et al.. (2011). An anatomical study of the myelination of human laryngeal nerves. The Journal of Laryngology & Otology. 125(12). 1263–1267. 2 indexed citations

17.

Kelly, William, Piers J. Ingram, & Michael P. H. Stumpf. (2011). The Degree Distribution of Networks: Statistical Model Selection. Methods in molecular biology. 804. 245–262. 7 indexed citations

18.

Ingram, Piers J., Michael P. H. Stumpf, & Jaroslav Stark. (2008). Nonidentifiability of the Source of Intrinsic Noise in Gene Expression from Single-Burst Data. PLoS Computational Biology. 4(10). e1000192–e1000192. 26 indexed citations

19.

Silva, Eric de, Thomas Thorne, Piers J. Ingram, et al.. (2006). The effects of incomplete protein interaction data on structural and evolutionary inferences. BMC Biology. 4(1). 39–39. 52 indexed citations

20.

Ingram, Piers J., Michael P. H. Stumpf, & Jaroslav Stark. (2006). Network motifs: structure does not determine function. BMC Genomics. 7(1). 108–108. 162 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact